Table 4.

Lymph node T lymphocytes from SIV gag plasmid DNA-vaccinated monkeys demonstrate secondary Gag epitope-specific CTL responses after SIVsm E660 challenge

ImmunizationMonkeyAssayValue at indicated day postchallenge
142842
SIVgag P091% Fresha 17.57.32.6
% Peptide stimulatedb 28.020.2NDd
% Specific Lysisc 55.064.9ND
N529% Fresh9.34.34.2
% Peptide stimulated12.34.2ND
% Specific lysis59.026.1ND
T258% Fresh0.10.61.1
% Peptide stimulated2.68.86.3
% Specific lysis21.236.720.7
9298% Fresh6.54.44.1
% Peptide stimulated9.47.23.9
% Specific lysis45.516.59.7
ControlP967% Fresh0.80.50.8
% Peptide stimulated50.617.1ND
% Specific lysis56.741.8ND
R468% Fresh2.20.40.2
% Peptide stimulated64.16.5ND
% Specific lysis65.827.5ND
T720% Fresh0.21.11.7
% Peptide stimulated0.810.87.3
% Specific lysis0.025.114.4
V299% Fresh0.7NDND
% Peptide stimulated31.0NDND
% Specific lysis63.8NDND
J8N% Fresh0.72.75.6
% Peptide stimulated3.38.62.3
% Specific lysisNDND0.3
  • a Lymphocytes from freshly obtained lymph nodes were directly assessed for binding of the Mamu-A*01/p11C tetramer to CD8αβ+ T cells.

  • b Lymph node cells were cultured in vitro with p11C peptide (10 μg/ml) for 12 days and then assessed for binding of the Mamu-A*01/p11C tetramer to CD8αβ+ T cells.

  • c Lymph node cells were cultured in vitro with p11C peptide (10 μg/mL) for 12 days and then assessed for p11C-specific lysis using a standard 51Cr release assay. Data represent percent p11C-specific lysis at an effector-to-target ratio of 10:1.

  • d ND, not done.